Background/Aim: Head and neck cancers account for 8% of all cancer cases worldwide. However, identifying the optimal treatment for recurrent or metastatic head and neck cancer (R/MHNSCC) has been challenging. The aim of this study was to evaluate the efficacy, safety, and prognostic factors of the outcome of patients with R/MHNSCC who were treated with weekly cetuximab and paclitaxel (Cmab-PTX). Patients and Methods: The records of R/MHNSCC patients who were treated with Cmab-PTX in our institution between June 2013 and September 2017 were collected. We analyzed Overall survival (OS), progression-free survival (PFS), prognostic factors and adverse events. Results: The records of 59 patients treated with Cmab-PTX were analyzed. The median PFS was 5.7 months, and the median OS was 11.8 months. Patients who had been administered cetuximab previously had shorter PFS and OS than those who had not. Conclusion: Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients.

中文翻译：

---

每周一次西妥昔单抗和紫杉醇治疗复发性或转移性头颈部鳞状细胞癌

背景/目的：头颈癌占全球所有癌症病例的 8%。然而，确定复发性或转移性头颈癌 (R/MHNSCC) 的最佳治疗方法一直具有挑战性。本研究的目的是评估接受每周一次西妥昔单抗和紫杉醇 (Cmab-PTX) 治疗的 R/MHNSCC 患者的疗效、安全性和预后因素。患者和方法：收集2013年6月至2017年9月在我院接受Cmab-PTX治疗的R/MHNSCC患者记录。我们分析了总生存期 (OS)、无进展生存期 (PFS)、预后因素和不良事件。结果：分析了 59 名接受 Cmab-PTX 治疗的患者的记录。中位 PFS 为 5.7 个月，中位 OS 为 11.8 个月。之前接受过西妥昔单抗治疗的患者的 PFS 和 OS 比未接受治疗的患者短。结论：Cmab-PTX 可作为头颈部 R/MHNSCC 患者的治疗选择。